Back to mobile site

Legend Biotech (LEGN) Reiterated at Overweight by Cantor Fitzgerald

December 17, 2025 7:23 AM EST Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and $74.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login